David Moreno, Director of Translational Cell Sciences at UCB, shared on LinkedIn:
“The conclusions of fresh CAR-T delivery clinical study ATALANTA-1 are out.
7-days vein to vein achieved but CAR-T manufacturing remains challenging, has risks associated and the added value of using fresh cells it is not demonstrated yet.
ATALANTA-1 conclusions are clear.”
Read the full article:
Article: CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study
Authors: Marie José Kersten, Maria T. Kuipers, Pim G. N. J. Mutsaers, Evelyne Willems, Kirsten Saevels, Martin Dreyling, Caron Jacobson, Michael R. Bishop, Maarten Zandvliet, Stavros Milatos, Chiara Lobetti-Bodoni, Sandra Blum, Kirsten van Hoorde, Jigar Desai, Lorenzo Acciarri, Margot J. Pont, Anna van Muyden, Omotayo Fasan, Joost S. P. Vermaat, Sébastien Anguille
You may also be interested in:
What Happens If CAR T-Cell Therapy Fails? Relapse, Refractory Disease, and Next Treatment Options
